Skip to main content
Ascentage Pharma Group International logo

Ascentage Pharma Group International — Investor Relations & Filings

Ticker · 6855 HKEX Manufacturing
Open in API
Filings indexed 405 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country HK Hong Kong
Listing HKEX 6855

About Ascentage Pharma Group International

https://www.ascentage.cn

Ascentage Pharma Group International is a global, integrated biopharmaceutical company dedicated to discovering, developing, and commercializing novel small molecule therapies with first-in-class or best-in-class potential. The company primarily targets unmet medical needs in cancers, chronic hepatitis B virus (HBV), and age-related diseases. Its core scientific strategy focuses on restoring intrinsic apoptogenic forces (programmed cell death) in cancer cells. Key commercialized and late-stage assets include the third-generation BCR-ABL inhibitor Olverembatinib and the novel Bcl-2 inhibitor Lisaftoclax (APG-2575). Ascentage maintains a robust global clinical development program, conducting over 40 trials across multiple continents, supported by numerous US FDA and EU Orphan Drug Designations and strategic partnerships with leading pharmaceutical and academic institutions worldwide.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA RELEASES LATEST CLINICAL DATA FROM MULTIPLE TRIALS AT ASCO 2026
Regulatory Filings Classification · 85% confidence The document is a voluntary announcement on the Hong Kong Stock Exchange website disclosing clinical trial data and abstracts selected for presentation at ASCO 2026. It contains no financial results, no management or board changes, no dividend or capital transactions, and is clearly an announcement rather than a formal report or filing such as an annual report, interim report, earnings release, proxy statement, or M&A document. It therefore falls into the fallback category for general regulatory announcements (RNS).
2026-05-22 English
THIRD AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION
Governance Information Classification · 95% confidence The document is the Third Amended and Restated Memorandum and Articles of Association of Ascentage Pharma Group International. It sets out the company’s internal rules, share structure, board composition, meetings, voting rights, and other governance provisions. This is a corporate charter/governance document, fitting the Governance Information category (CGR).
2026-05-21 English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 20, 2026
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an official announcement of the poll results from the Annual General Meeting held on May 20, 2026, detailing the number of votes for and against each resolution. This matches the definition for Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-20 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return report for an equity issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules. It provides comprehensive data on movements in authorised share capital, issued shares, treasury shares, share options, and confirmations related to compliance with listing rules. The document is submitted to the Hong Kong Exchanges and Clearing Limited and includes specific monthly data for April 2026. It is not an announcement of a report, nor a certification letter, but a regulatory filing providing detailed monthly share capital and share movement information as required by the exchange. This type of document fits the category of Regulatory Filings (RNS) as it is a compliance and disclosure filing that does not fall under other specific categories like capital changes (SHA) or director dealings (DIRS).
2026-05-07 English
SECOND FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MAY 20, 2026
AGM Information Classification · 95% confidence The document is a form of proxy for the Annual General Meeting (AGM) of Ascentage Pharma Group International scheduled for May 20, 2026. It includes instructions for shareholders on how to appoint proxies to vote on various resolutions at the AGM, including adoption of financial statements, re-election of directors, and other corporate matters. The document is not the AGM presentation or materials themselves, but a proxy form related to the AGM. This fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM, including proxy forms and voting materials. The document length is 9154 characters, which is consistent with a detailed proxy form. Therefore, the appropriate classification is AGM Information (AGM-R).
2026-04-30 English
SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 95% confidence The document is titled 'SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING' and references an original AGM notice and supplemental circular. It details additional resolutions to be considered at the AGM, including the grant of RSUs and options to certain directors. It also discusses proxy forms and voting instructions for shareholders. The content is clearly related to the notice and procedural information for an Annual General Meeting, not the actual AGM materials or presentations themselves. The document length is about 6007 characters, which is relatively short and consistent with a notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM, including notices and supplemental notices.
2026-04-30 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.